Immix Biopharma, Inc. (IMMX) Stock: Dividends & Earnings

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $2.00 - $15.10

4.8 Year IMMX Performance Metrics:

Total Return (with DRIP): 183.7% (24.26% CAGR)

Total Return (no DRIP): 183.7% (24.26% CAGR)

Share Price: 183.7% (24.26% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $28,365

Total Return $ (with DRIP): $18,365

IMMX Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

IMMX Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for IMMX

Based on past 4.8-year performance, here are IMMX growth metrics:

Share price CAGR of +24.26%
Dividend CAGR of +0%

Using IMMX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	IMMX (DRIP)	IMMX - No DRIP
Current Price	$10.41	$10.41
Start Shares	960.61	960.61
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	960.61	960.61
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$10.41	$10.41
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - IMMX

NOTE: Above numbers are our estimate based on IMMX's Dividend and Price CAGR over past 4.8 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Immix Biopharma, Inc. (IMMX) had its IPO on , and is traded on NASDAQ stock exchange.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers. Immix Biopharma’s current pipeline is led by NXC-201, a BCMA-targeted CAR-T cell therapy being evaluated for AL amyloidosis and related plasma-cell disorders, and IMX-110, a tissue-specific therapeutic studied in solid tumors. The company also works on immune-dysregulated and inflammatory diseases through its proprietary therapeutic platforms. Immix Biopharma operates in the biotechnology sector, where its role is centered on advancing investigational treatments designed to address high-unmet-need conditions through cell therapy and precision drug delivery approaches. Founded in 2012 and headquartered in Los Angeles, California, Immix Biopharma is positioned as a development-stage company focused on translating specialized oncology and immunology research into clinical programs.

IMMX website: https://www.immixbio.com